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Abstract
Many neurodegenerative diseases are characterized by the conformational change of normal self-proteins into
amyloidogenic, pathological conformers, which share structural properties such as high b-sheet content and resistance
to degradation. The most common is Alzheimer’s disease (AD) where the normal soluble amyloid b (sAb) peptide is
converted into highly toxic oligomeric Ab and fibrillar Ab that deposits as neuritic plaques and congophilic angiopathy.
Currently, there is no highly effective treatment for AD, but immunotherapy is emerging as a potential disease modifying
intervention. A major problem with most active and passive immunization approaches for AD is that both the normal sAb
and pathogenic forms are equally targeted with the potential of autoimmune inflammation. In order to avoid this pitfall, we
have developed a novel immunomodulatory method that specifically targets the pathological conformations, by
immunizing with polymerized British amyloidosis (pABri) related peptide which has no sequence homology to Ab or other
human proteins. We show that the pABri peptide through conformational mimicry induces a humoral immune response not
only to the toxic Ab in APP/PS1 AD transgenic mice but also to paired helical filaments as shown on AD human tissue
samples. Treated APP/PS1 mice had a cognitive benefit compared to controls (p,0.0001), associated with a reduction in the
amyloid burden (p=0.0001) and Ab40/42 levels, as well as reduced Ab oligomer levels. This type of immunomodulation has
the potential to be a universal b-sheet disrupter, which could be useful for the prevention or treatment of a wide range of
neurodegenerative diseases.
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Introduction
The diagnostic neuropathological lesions of AD are the accumu-
lation of amyloid b (Ab)a sn e u r i t i cp l a q u e sa n dc o n g o p h i l i c
angiopathy, as well as aggregation of abnormally phosphorylated
tau in the form of neurofibrillary tangles (NFTs) [1]. AD is the most
common of the neurodegenerative protein conformational disorders,
which include diffuse Lewy body disease (DLBD), Parkinson’s disease
(PD), prion diseases, and frontotemporal lobar degeneration (FTLD).
In each of these disorders a normal self-protein/peptide, which has a
physiological function, undergoes a conformational change to a
pathological conformer that has a high b-sheet content, is resistant to
degradation and accumulates either in extracellular plaques or
intracellular inclusion bodies, with the most toxic conformers being
oligomeric [2]. In AD the normal soluble Ab (sAb)a n dt a ua r e
converted to Ab and abnormally phosphorylated tau in NFTs,
respectively. Eleven different proteins are known to accumulate as
oligomers, plaques and/or intra-cellular inclusions in the CNS
leadingtovariousneurodegenerativediseases,withthemostcommon
being Ab, phosphorylated tau, a-synuclein and TDP-43 [2;3].
Among patients with a clinical diagnosis of dementia, neuropatho-
logical examination reveals that in a majority of cases there is an
accumulation of a mixture of different pathological protein
conformers, with the most common mix being Ab, phosphorylated
tau and a-synuclein [4]. However, a continuum also exists between
AD and FTLD associated pathology with some 23–34% of AD cases
having TDP-43 inclusions [5;6]. One explanation for this frequent
co-occurrence of age associated pathologies in a given patient’s brain
is that one type of pathological conformer can seed oligomerization/
fibrillization in heterologous proteins which are prone to form
amyloid, in what has been called abnormal conformational mimicry
[7;8]. None of the conformational diseases has an effective therapy;
however, immunotherapy has shown great promise for both AD and
prion diseases, at least in mouse models [9;10]. However, potential
toxic side effects with these immunological approaches targeting a self
protein are autoimmune inflammatory complications. In the first
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encephalitis [11]. One possible way to avoid this is to use antibodies
that specifically target the pathological conformer [12]. A few studies
have tried conformation selective monoclonal antibodies therapeu-
tically in AD mouse models and found this to have beneficial effects
[13–15]. However, a major disadvantage to passive immunization for
chronic neurodegenerative disorders would be the need for multiple
infusions and the risk of developing anti-idiotypic immunity, which
would limit efficacy and be associated with toxicity.
In the present study we sought to develop therapeutic
immunomodulation through a conformation selective active
immunization approach and test it therapeutically in an AD
mouse model. This is an approach, which to our knowledge has
not been tried previously. In this novel active immunomodulation
approach, we used a polymerized British amyloidosis (ABri)
related peptide in a predominantly b-sheet, oligomeric form. ABri
is a rare form of familial human amyloidosis associated with a
missense mutation in a stop codon resulting in the transcription of
an intronic sequence, leading to production of a highly
amyloidogenic protein with a carboxyl terminus that has no
sequence homology to any other native human protein, including
Ab [16;17]. We hypothesized that through conformational
mimicry the polymerized ABri peptide could induce a conforma-
tion selective immune response that will recognize Ab (as well as
other potentially amyloidogenic proteins such as phosphorylated
tau). Such an immunostimulatory approach would have a reduced
risk of inducing auto-immune complications as it is specific to a
pathological conformer and the immunogen has no sequence
homology to any known mammalian protein/peptide. We tested
this approach in an APP/PS1 AD mouse model [18] and
evaluated for behavioral benefits and reductions in Ab related
pathology histologically and biochemically.
Materials and Methods
A) Synthesis of Peptide
The 13 residue peptide corresponding to the carboxyl terminus
of ABri (Cys-Ser-Arg-Thr-Val-Lys-Lys-Asn-Ile-Ile-Glu-Glu-Asn)
was synthesized on an ABI 430A peptide synthesizer (AME
Bioscience, Chicago, IL) at the Keck peptide synthesis facility at
Yale University, CT, using a Vydac C18 preparative column,
2.5630 cm (Vydac Separations, Hesperia, CA). Standard proto-
cols for tBOC (tert-butyloxycarbonyl) chemistry were used. The
peptide was subsequently cleaved from the resins using hydro-
fluoric acid and purified by high-pressure liquid chromatography
(HPLC) on a Vydac C18 preparative column using linear
gradients from 0–70% of acetonitrile in 0.1% trifluoroacetic acid.
Mass spectroscopy of the lyophilized end-product was used to
verify the expected molecular weight.
B) Polymerization of the ABri Peptide and Assessment of
Conformation
In order to make the 13 residue ABri peptide immunogenic and
to potentially ensure a conformation specific immune response, the
peptide was first subjected to controlled polymerization using the
following protocol: The peptide was dissolved at 3 mg/ml, in
100 mM borate buffer saline (BBS), pH 7.4. Fresh 1% glutaral-
dehyde in BBS was prepared and added to the peptide to a final
5 mM glutaraldehyde concentration and incubated in an
Eppendorf block shaker at 800 rpm and 56uC for 16 hrs. The
solution was then quenched with 0.5 M glycine to make the
solution 100 mM in glycine. After five minutes the solution was
diluted 1:3 with BBS, dialyzed against 2 mM BBS overnight at
4uC, aliquoted and lyophilized. To determine the degree of
aggregation the original monomeric ABri peptide and polymerized
ABri peptide (pABri) were electrophoresed on 12.5% SDS-
polyacrylamide Tris-tricine gels under reducing conditions.
Western blots were performed with a mouse anti-ABri polyclonal
Ab [19] (1:1,000 dilution) The secondary antibody (1:2,000
dilution) was peroxidase-linked anti-rabbit IgG (Amersham
Biosciences, Piscataway, NJ), and the immunoreactive material
was visualized as chemoluminescence on X-ray film with an ECL
detection kit (Pierce). For electron microscopic studies, the original
and polymerized ABri peptides were incubated at 1 mg/ml in
phosphate buffered saline, pH 7.4. 3 ml of sample was put onto a
carbon coated 400 mesh Cu/Rh grid (Ted Pella Inc., Redding,
CA) and stained with 1% uranyl acetate in distilled water
(Polysciences, Inc, Warrington, PA). Stained grids were examined
under a Philips CM-12 electron microscope (FEI; Eindhoven, The
Netherlands) and photographed with a (1k x1k) digital camera
(Gatan, Inc., Pleasanton, CA). For secondary structure analysis
aliquots of the original ABri peptide and pABri were reconstituted
in 5 mM Tris buffer (pH 7.0) to obtain a peptide concentration of
100 mM. Circular dichroism (CD) was measured on a Jasco J-720
spectropolarimeter (Easton, MD) equipped with a model CTC-
344 circular temperature control system (Neslab Inc., Newington,
NH) according to our previously described protocol [20]. The
neural network algorithm (Softsec software; Softwood Inc., PA)
was used to obtain percentages of different types of secondary
structures of the analyzed peptides [21;22].
C) Purification of paired helical filaments (PHF)
PHF were purified from the brain of a subject from the New
York University Alzheimer’s Disease Center brain bank, who
fulfilled the National Institute on Aging-Reagan criteria for AD at
autopsy by using a modification of a method previously reported
[23],. Briefly, 30 gm of frontal cortex was homogenized in 75 ml
of 50 mM Tris-buffered saline (TBS), pH 7.4 using an Ultra
Turrox T25 tissue homogenize (IKA Works, Inc; Staufen,
Germany). 75 ml of 20% sarcosyl in H2O was added to the
sample and it was homogenized again. The homogenized material
was centrifuged at 3,500 rpm in a Beckman GPR centrifuge and
6 ml aliquots of the supernatant were each layered over 1 ml
TBS/0.1%SB3-14 and centrifuged in an Optima Max ultracen-
trifuge at 75,000 rpm for 2 hours at 20uC. Each pellet was
resuspended by sonication in1 ml of 10%NaCl in TBS/0.1%SB3-
14, followed by the addition of 6 ml of 10%NaCl in TBS/
0.1%SB3-14 and centrifuged at 75,000 rpm for 1.5 hours at 20uC.
The pellets were sonicated in 1 ml of 10%NaCl in TBS/
0.1%SB3-14 followed by the addition of 6 ml of 10%NaCl in
TBS/0.1%SB3-14, layered over 1 ml of 20% sucrose in 10%NaCl
TBS/0.1%SB3-14 and centrifuged at 75,000 rpm for 1.5 hours at
20uC. The final pellets were resuspended in TBS/0.1%SB3-14 by
sonication prior to use.
D) Immunization of Mice
Animal studies were approved by the NYU School of Medicine
Institutional Animal Care and Use Committee (protocol 070503-
03) and were consistent with the recommendations of the
American Veterinary Association. The pABri peptide was
dissolved in sterile saline at 1 mg/ml and mixed 1:1 with
Aluminum Hydroxide (Alum) adjuvant (Brenntag Biosector,
Denmark). Each mouse received a weekly subcutaneous injection
of 100 ml of the preparation for 4 weeks followed by an inoculation
a month later and two subsequent bimonthly injections. The last
three inoculations used 25 mg of pABri per animal and the ratio
of saline to alum ratio was changed to 9:1. Two groups of 15
APP K670N/M671L/PS1 M146L (APP/PS1) Tg mice [18] were
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alum alone starting at the age of 2 months, with the mouse
breeding and genotyping as previously described [24]. Animals
were bled from the caudal vein one week after the 4th and 6th
inoculations (T4 and T6, respectively) and at the time of sacrifice
(TF). The blood was collected in heparinized tubes and plasma
separated and stored at 280uC. Amyloid deposition in this mouse
AD Tg model starts at about the age of 3 months [25]. At the age
of 14 months the two groups of Tg mice were subject to behavioral
testing using the radial arm maze with comparison to a third group
of 15 mice which were age and sex matched, non-Tg littermate
controls which had been given sc injections of saline/alum alone.
E) Sensorimotor and Cognitive testing
Sensorimotor and cognitive testing were done as previously
described [24;26;27]. Prior to testing, the mice were adapted to the
room with lights on for 15 min. The main objective of performing
these sensorimotor tasks was to verify that any treatment related
effects observed in the cognitive tasks could not be explained by
differences in sensorimotor abilities.
Locomotor Activity
A Hamilton-Kinder Smart-frame Photobeam System was used
to make a computerized recording of animal activity over a
designated period of time. Exploratory locomotor activity is
recorded in a circular open field activity chamber measuring
(70670 cm). A video camera mounted above the chamber
automatically recorded horizontal movements in the open field
in each dimension (i.e., x, y, and two z planes). Total distance was
measured in centimeters (cm) traveled and is defined as sequential
movement interruptions of the animal measured relative to the
background. The duration of the behavior was timed for 15 min.
Results were reported based on distance traveled (cm), mean
resting time, and maximum velocity of the animal.
Traverse Beam
This task tests balance and general motor coordination and
function integration. Mice were assessed by measuring their ability to
traverse a graded narrow wooden beam to reach a goal box
specifically examining hind limb function. The mice were placed on a
1.1 cm wide beam 50.8 cm long suspended 30 cm above a padded
surface by two identical columns. Attached at each end of the beam
was a shaded goal box. Mice were placed on the beam in a
perpendicular orientation to habituate, and were then monitored for
a maximum of 60 sec. The number of foot slips each mouse has
before falling or reaching the goal box was recorded for each of three
successive trials.The average foot slips for allfour trials was calculated
and recorded. Errors are defined as foot slips and recorded both
numerically and using Feeney scores. To prevent injury from falling,
a soft foam cushion was always kept underneath the beam. Animals
that fell off were placed back in their position prior to the fall.
Rotarod
The animal was placed onto the rod (diameter 3.6 cm)
apparatus to assess differences in motor coordination and balance
by measuring fore- and hind limb motor coordination and balance
(Rotarod 7650 accelerating model; Ugo Basile, Biological
Research Apparatus, Varese, Italy). This procedure was designed
to assess motor behavior without a practice confound. The animals
were habituated to the apparatus by receiving training sessions of
two trials, sufficient to reach a baseline level of performance. Then
the mice were tested a further 3 times, with increasing speed.
During habituation, the rotor rod was set at 1.0 rpm, which was
gradually raised every 30 sec, and was also wiped clean with 30%
ethanol solution after each session. A soft foam cushion was placed
beneath the apparatus to prevent potential injury from falling.
Each animal was tested for three sessions, with each session
separated by 15 min, and measures were taken for latency to fall
or invert (by clinging) from the top of the rotating barrel.
Radial Arm Maze
Spatial learning was evaluated using an eight-arm radial maze
with a water well at the end of each arm. Clear Plexiglas guillotine
doors, operated by a remote pulley system, controlled access to the
arms from a central area from which the animals entered and
exited the apparatus. After 4 days of adaptation to the maze,
water-restricted mice (2 h daily access to water) were given one
training session per day for ten consecutive days. We use this
relatively long adaptation period as we have found that these Tg
AD mice tend to be very anxious and will not run the maze well
without adaptation [24;27]. Prior to each day’s testing, the mice
were adapted to the room with lights on for 15 min. For each
session, all arms were baited with saccharine flavored water, and
animals were permitted to enter all arms until the eight rewards
had been consumed. The number of errors (entries to previously
visited arms) and time to complete each session were recorded.
F) Antibody levels
Antibody levels were determined in duplicate on 1:100 dilutions of
plasma using ELISAas described previously [27;28], in which50 mg/
plate Ab1-42, pABri or purified PHF was coated onto Immulon 2HB
96 well microtiter wells (Thermo, Waltham, MA). The bound
antibodies were detected by a horseradish peroxidase labeled goat
anti-mouse IgG (Amersham Biosciences, Piscataway, NJ) or a
peroxidase conjugated goat anti-mouse IgM (Sigma; A8786).
Tetramethyl benzidine (TMB; Pierce, Rockford, IL) was the color
developing substrate and the readings were done at 450 nm.
G) Histology
Mice were anesthetized with sodium pentobarbital (150 mg/kg,
i.p.), perfused transaortically with phosphate buffer, and the brains
processed as described previously [27;29]. The right hemisphere
was immersion-fixed in periodate-lysine-paraformaldehyde, where-
as the left hemisphere was snap-frozen for measurements of Ab
levels. Serial coronal sections (40 mm) were cut, and every fifth
section (30–40 sections in total) was stained with a mixture of 4G8/
6E10, monoclonal antibodies that recognizes Ab and stains both
pre-amyloid and Ab plaques [24;30]. In addition two series of
sections were immunostained with anti-GFAP and anti-CD11b
antibodies. GFAP is a component of the glial intermediate filaments
that forms part of the cytoskeleton and is found predominantly in
astrocytes. CD11b is a member of the b-integrin family of adhesion
molecules; also known as MAC-1 or complement receptor 3 [CR3])
and is commonly used as a marker for microglia [31;32].
Immunostaining was performed as described previously [24;30].
Briefly, sections were incubated in 6E10/4G8 each at a 1:1000
dilution in PBS-T for 3 h. A mouse-on-mouse immunodetection kit
(Vector Laboratories, Burlingame, CA) was used. The sections were
incubated first with biotinylated anti-mouse IgG secondary
antibody for 1 h at a 1:2000 dilution and later with the avidin-
peroxidase complex for 30 min at the same dilution. The sections
were then reacted in 3,3-diaminobenzidine tetrahydrochloride with
nickel ammonium sulfate (Ni; Mallinckrodt, Paris, KY) color
intensification solution. Immunohistochemistry of 6E10/4G8 im-
munolabeled tissue sections was quantified with a Bioquant image
analysis system (BIOQUANT Image Analysis Corporation, Nash-
ville, TN), and unbiased sampling was used [30]. All procedures
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conditions of the study. The cortical area analyzed was dorsomedial
from the cingulate cortex and extended ventrolaterally to the rhinal
fissure within the right hemisphere. The area of the grid was
800 mm
26800 mm
2,a n dA b deposit load was measured in 20
cortical frames per mouse (6406480 mm
2 each) chosen randomly.
The threshold of the Ab immunoreactive areas is set so that areas of
,5 mm in diameter are not counted. This is done so that small
artifactual areas of staining are not counted and intra-neuronal
immunoreactivity is also not counted. With the latter caveat, the Ab
burden is defined as the percentage of areain the measurement field
occupied by reaction product.
GFAP staining (polyclonal, 1:1000; 3 h, Dako, Denmark) was
performed with a primary antibody diluent composed of 0.3%
Triton X-100, 0.1% sodium azide, 0.01% bacitracin, 1% bovine
serum albumin (BSA), and 10% normal goat serum in PBS, and
secondary biotinylated goat anti-rabbit antibody (Vector) reacted
for 1 h at 1:1000 dilution. CD11b immunohistochemistry (rat anti-
mouse, 1:500; 3 h, Serotec) was performed similarly to that for
GFAP staining except that the secondary antibody was goat anti-
rat (Vector) diluted 1:1000. Reactive astrocytosis (GFAP immu-
noreactivity) was rated on a scale of 0–4. The rating was based on
a semiquantitative analysis of the extent of GFAP immuoreactivity
(number of GFAP immunoreactive cells and complexity of
astrocytic branching), as we have previously published [27;30].
The assessment of the CD11b immunostained sections was based
on a semiquantitative analysis of the extent of microgliosis (0, no
microglia; 1, a few resting microglia; 2, a few ramified and/or
phagocytic microglia; 3, moderate number of ramified/phagocytic
microglia; 4, numerous ramified/phagocytic microglia), as we
have previously reported [27;30].
Plasma from vaccinated mice with the highest titer to Ab1-42
and PHF, as well as the pre-immune (T0) plasma from the same
mice (as a control), was used for immunostaining of human tissue.
Staining was performed on 8 mm deparaffinzed sections of
temporal cortex. Tissue samples were of subjects from the New
York University Alzheimer’s Disease Center Brain Bank, who
fulfilled the National Institute on Aging-Reagan criteria for AD or
were age matched controls with no AD related pathology (or other
neuropathology) at autopsy. Selected series were double-immuno-
stained with pooled plasma from pABri immunized Tg mice and
either PHF-1 mAb (to abnormally phosphorylated tau protein
[33]) or anti-Ab using a mixture of monoclonal 4G8 and 6E10
[30]. Briefly, sections were incubated overnight at 4uC with pooled
plasma from the T6 bleedings of pABri immunized Tg mice
diluted 1:100 in PBS, 0.1% Triton X-100, 0.01% sodium azide
and 1% BSA. Bound antibody staining was performed with a
secondary biotinylated goat anti-mouse IgM (mu chain specific,
Vector Laboratories) incubated for 1 h at a 1:500 dilution. First,
primary antibody staining was revealed with 3,39-diamonobenzi-
dine (DAB Sigma-Aldrich) and nickel ammonium sulfate intensi-
fication. After several washes, the tissue was blocked again in PBS
10% FBS, 0.2% Triton X-100 and the second primary antibody
PHF-1 (monoclonal, 1:200; 1 h) or a mixture of anti-Ab 4G8/
6E10 (1:1000 each, 1 h) was added, followed by incubation with
alkaline phosphatase labeled horse anti-mouse IgG (1:500, 1 h;
Vector Laboratories). Next an alkaline phosphatase substrate kit
(Vector) was applied to produce a red reaction product.
In addition to using non-AD tissue as a control of specific
immunoreactivity with plasma from pABri vaccinated mice, we
absorbed the immune plasma with aggregated/oligomeric Ab1-42
for immunostaining.: In order to prepare aggregated Ab for
absorption, 1 mg of synthetic Ab 1–42 was dissolve in 200 mLo f
1,1,1,3,3,3 hexafluoro-2-propanol (HFP) (Sigma). The mixture
was let stand at room temperature until the solvent was
evaporated, and 1 mL of 50 mM TRIS pH 7.2 was added under
sterile conditions. The mixture was kept at room temperature for
month until clear fibrils could be seen. Electron microscopic
examination of this preparation demonstrated it to be a mixture of
mainly Ab1-42 fibrils, and some oligomers (data not shown). The
mixture was thoroughly vortexed before aliquoting for absorption.
For absorption, 1 mL of a 1:100 dilution in TBS of an immune
serum from successfully vaccinated animals was mixed with
200 mL of the aggregated Ab 1-42, rotated for 1 hour at room
temperature and then overnight (for at least 16 hours) at 4uC. The
mixture was centrifuged at 4uC, at 14,0006g for 15 minutes and
the supernatant separated and used as absorbed serum for
immunohistochemical staining as described above. The pellet
composed of aggregated Ab1-42 was washed twice with 0.5 mL of
TBS, centrifuged at 14,0006 g for 10 minutes and the
supernatants pooled and marked as washes. The pellet was then
incubated twice for 5 minutes with 300 mL aliquots of 0.1 M
glycine, pH 2.5, vortexed and centrifuged for 10 minutes at
14,0006g. The supernatants were pooled and immediately
brought to pH 7.4 with a 1 M TRIS, pH 10 solution, and used
as eluted antibodies for immunostaining as described above.
H) Tissue homogenization and sandwich ELISA assay for
soluble Ab levels
Extraction of Ab from brain tissue was performed as described
[30]. Brains were weighed and homogenized (10% w/v) in
homogenization buffer, 20 mM Tris, 250 mM sucrose, 1 mM
EDTA, 1 mM EGTA with freshly prepared 100 mM phenyl-
methylsulfonyl fluoride, 5 mg/ml pepstatin A and a protease
inhibitor cocktail (Complete, Roche Diagnostics, Indianapolis,
IN). For extraction of soluble Ab, brain homogenates were
thoroughly mixed with an equal volume of 0.4% diethylamine
(DEA)/100 mM NaCl, then spun at 135,0006 g for 1 hour at
4uC, and subsequently neutralized with 1/10 volume of 0.5 M
Tris, pH 6.8. The samples were then aliquoted, flash-frozen on
dry ice, and stored at –80uC until loaded onto ELISA plates.
Similarly for extraction of the total Ab, 200 ml of each homogenate
was added to 440 ml of cold formic acid (FA) and sonicated for one
minute over ice. Subsequently, 400 ml of the solutions were spun at
100,000 g for 1 hour at 4uC. 210 ml of the resulting supernatants
were diluted with 4 ml of FA neutralization solution (1 M Tris, 0.5
MN a 2HPO4, 0.05% NaN3), aliquoted, flash-frozen on dry ice and
stored at 280uC until used for Ab measurements.
The total and soluble Ab levels were measured using a
combination of mouse monoclonal antibody 6E10 (specific to
an epitope present on amino acid residues 1 to 16 of Ab)a n dt w o
different rabbit polyclonal antibodies specific for Ab40 (R162)
and Ab42 (R165), in a double-antibody sandwich ELISA as
described previously [24;30]. The optical density (OD) was
measured at 450 nm. The relationship between OD and Ab
peptide concentration was determined by a four-parameter
logistic log function. Non-linear curve fitting was performed with
the KinetiCalc program (Biotek Instruments, Inc., Winooski, VT)
to convert OD of plasma to estimated concentrations. The assay
was performed by an investigator blinded to group assignment.
The levels of Ab species are presented as mgo fA b per g of wet
brain, taking into account dilution factors introduced by multiple
steps throughout the assay (brain homogenization and extraction
procedures).
I) Western Blot analysis of Ab oligomers
For Western immunoblot analysis, 10% w/v brain homogenates
were centrifuged at 25,000 g for 10 min at 4uC, and the
Conformational Vaccine for AD
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previously described [24;30]. The total protein concentration in
the supernatant was determined using the Bicinchoninic acid assay
(BCA; Pierce, Rockford, IL). Samples (40 mg of total protein), were
mixed with an equal volume of Tricine sample buffer (BioRad,
Hercules, CA), were electrophoresed on 12.5% Tris-tricine
polyacrylamide gels, under nonreducing conditions and trans-
ferred to nitrocellulose membranes. The blots were blocked with
5% nonfat dry milk in TBS-T, pH 8.3, for 2 hours at room
temperature, then incubated with oligomer-specific rabbit A11
polyclonal antiserum (Biosource, Camarillo, CA), diluted 1:1000
in TBS-T, 0.1% BSA for 2 hrs at room temperature. Bound
antibody was detected after 1 hr incubation with horseradish
peroxidase-conjugated goat anti-rabbit IgG 1:8000 (Pierce, Rock-
ford, IL) and the ECL detection system (Pierce, Rockford, IL). The
specificity of A11 staining was confirmed by Western blots of the
same samples using anti-Ab monoclonal antibodies 6E10 or 4G8
as previously described [24]. Densitometric analysis of A11
immunoreactive oligomer specific bands was performed with
NIH Image J version 1.34 software.
J) Statistical analysis
Data from the radial arm maze were analyzed by two-way
repeated measures ANOVA followed by a Neuman-Keuls posthoc
test. Differences between groups in the amyloid burden, Ab levels
within the brain and levels of oligomers, were analyzed using a
Student’s unpaired two-tailed t-test. Data from the GFAP and
CD11b immunostaining quantitation were analyzed by one-way
ANOVA followed by a Neuman-Keuls posthoc test. Statistical
analysis was done using GraphPad Prism version 5.0 (GraphPad
Software Inc., La Jolla, CA).
Results
A) Characterization of the aggregation state of the pABri
and its conformation
As determined by SDS-PAGE and Western blotting the freshly
dissolved ABri peptide is mainly monomeric with some lower order
aggregates of dimers and tetramers (Figure 1A, lane 1). The pABri
had a lower percentage of monomeric form, an increase of
multimers and a predominance of higher order aggregates in a
range of 30 to 100 kDa (Figure 1A, lane 2). The apparent molecular
weight of pABri monomers appears to be lower then those of the
fresh sample, most likely reflecting the differing conformational
states of these peptides and the amount of bound SDS. Circular
dichroism of these peptides indicated that the freshly dissolved ABri
peptide has a predominant random coil structure with a minimum
at 195 nm, in contrast to the pABri that had a predominantly b-
sheet structure with a minimum at 220 nm and a maximum at
195 nm (Figure 1B). The electron microscopic appearance of the
pABri is predominately spherical particles of ,10 nm, similar to
what has been reported for other amyloid oligomers (Figure 1C)
[34;35]. In contrast the mainly monomeric, freshly dissolved ABri
peptide did not form any structures such as spherical particles or
fibrils by electron microscopy (data not shown).
B) Antibody titers
In vehicle control mice there were no significant titers to pABri,
Ab1-42 or purified PHF (Figure 2A and B). In the pABri
vaccinated mice, significant IgG and IgM titers were noted against
Ab42, polymerized ABri and purified PHF (p value by unpaired t-
test was p,0.0001 and p,0.01 for IgM and IgG respectively for
both the bleedings at T6 and TF) (See Figure 2C and D).
Figure 1. Characterization of polymerized ABri. A Western blot using specific polyclonal anti-ABri antisera is shown in panel A. The freshly
dissolved ABri peptide was run in lane 1. This preparation of ABri is mainly monomeric with some lower order aggregates of dimers and tetramers in
contrast to the polymerized ABri peptide which has less monomer with a predominance of higher order aggregates in a range of 30 to 100 kDa (lane
2). Shown in panel B is the circular dichroism of these peptides. The freshly dissolved ABri peptide has a predominant random coil structure with a
minimum at 195 nm, in contrast to the polymerized ABri peptide that has a predominant b-sheet structure with a minimum at 220 nm and a
maximum at 195 nm. In panel C an electron micrograph of negatively stained polymerized ABri peptide is shown, which is predominately in the form
of spherical particles of ,10 nm (Scale bar, 100 nm).
doi:10.1371/journal.pone.0013391.g001
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In order to verify that cognitive testing was not confounded by
differences in sensorimotor abilities in the ABri vaccinated versus
control mice, sensorimotor testing was conducted first. There were
no significant difference between the groups in locomotor activity
(see Figure 3), traverse beam testing and rotarod testing (data not
shown).
Radial arm maze cognitive testing showed there were statistically
significant differences between the untreated control Tg mice versus
the treated Tg mice and wild-type controls (Figure 4). By two-way
ANOVA the treatment effect was p,0.0001 and the day effect was
p=.01. Post-hoc Neuman-Keuls testing indicated that both the
wild-type controls and treated Tg mice were significant different
from the control Tg mice (p,0.001). There was no difference
between the wild-type controls and the treated Tg mice. The mean
error rate on day 1 was 4.5 and 5.3 versus 2.6 and 2.5 on day 10 in
the treated Tg mice (p,0.05, by two-tailed t-test) and the wild-type
controls (p,0.01, by two-tailed t-test), respectively, indicating that
both groups showed learning over time. In the Tg non-treated
controls the mean day1 error rate was 11.4versus 9.9on day 10 (no
statistically significant difference), indicating that these mice did not
learn over time.
D) Amyloid Quantitation by Stereology and Biochemical
Analysis
There were significant reductions in the amyloid burden (%
area occupied by 4G8/6E10 immunoreactivity) in both the cortex
(85% reduction) and hippocampus (65% reduction); p=0.0001
and p=0.0002, respectively (see Figure 5A and B). The amyloid
burdens we calculated in these Tg mice are similar to what we and
others have previously reported [24;26;36–38]; however, the
burdens are less than in other reports [39]. This variability is likely
related to differing experimental procedures between laboratories.
Representative immunostained sections are shown in Figure 5C-F
(scale bar =200 mm).
Significant reductions in the biochemically extracted Ab40 and
Ab42 levels were also noted (Figure 6). In the formic acid extract
fraction Ab40 and Ab42 were reduced 64% and 53%, respectively
(p,0.0001). In the DEA extracted fraction Ab40 (p,0.0001) and
Ab42 (p=.0002) were reduced by 71% and 57%, respectively, (p
values are by unpaired, two-tailed t-tests).
E) Immunostaining of AD tissue by plasma from
immunized mice
Plasma (T6) from pABri vaccinated Tg mice gave no
immunolabeling in normal, aged brain sections (Figure 7A). In
AD temporal cortex sections, extensive cytoplasmic neuronal
immunoreactivity is evident (Figure 7B). Absorption of the
immune plasma with aggregated Ab1-42 resulted in loss of
neuronal immunolabeling (Figure 7C). Figure 7D shows a higher
magnification of the lack of specific labeling with plasma from a
pABri vaccinated Tg mouse on normal brain tissue. In Figure 7E a
higher magnification of the neuronal cytoplasmic and dendritic
immunolabeling is shown (see arrows). Figure 7F depicts doubling
labeling where the neuronal staining with the immune plasma is
seen in black and neurofibrillary tangle immunolabeling with
PHF-1 is seen in red (see arrows). Hence some neurofibrillary
tangles immunolabeled with both PHF-1 and the plasma from
pABri vaccinated mice. In Figure 7G immunostaining with plasma
which had been absorbed with aggregated Ab1-42 on an AD
temporal cortex section is shown. Figure 7H shows immunolabel-
ing in a sequential section to G using plasma which had been
eluted from the aggregated Ab1-42 pellet. Figure 7I shows
immunolabeling with PHF-1 in a sequential section. The arrows
show labeling of dystrophic neurites with the eluted immune
mouse plasma in Figure 7H and with PHF-1 in Figures 7I.
Figures 7J, K and L depict a similar series of pictures using a
different plasma sample from a Tg mouse immunized with pABri,
showing a lack of specific labeling in J, immunolabeling of
dystrophic neurites with the eluted plasma sample in K and the
matching PHF-1 labeling in L. Rare amyloid b plaques also
showed faint immunolabeling with plasma from pABri immunized
mice, as shown in Figure 7M (see arrows). Figure 7N shows a
double immunolabeling where the plasma from a pABri
Figure 2. Antibody levels in control and pABri vaccinated mice. Shown are bar graphs of the IgG and IgM antibody levels against
polymerized ABri, Ab42 and PHF at T0, T6 and TF. In A and B, titers of IgM and IgG in controls are shown, respectively. In C and D, titers of IgM and IgG
in pABri vaccinated mice are shown, respectively (*p,0.0001, #p,0.01).
doi:10.1371/journal.pone.0013391.g002
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(see black arrows) and Ab immunoreactivity is seen in red (see red
arrows). There is no co-localization of the plasma immunolabeling
with the anti-Ab 4G8/6E10 immunolabeling. Figure 7O depicts a
lack of specific immunolabeling at a lower magnificent of a similar
temporal cortex AD section to Figures 7M and N where the pre-
immune (T0) plasma was used from the same mouse. This pattern
of staining is similar to what has previously been reported with an
anti-Ab oligomer polyclonal mouse sera [40].
F) Quantitation of Ab oligomers
Soluble oligomeric Ab ligands (also known as ADDLs) may
account for memory loss and AD neuropathology, thus presenting
a significant therapeutic target [41]. The level of pathogenic Ab
oligomers in the brain homogenates were assessed by Western-blot
using the A11 oligomer-specific antibody (Figure 8, top left). The
A11 immunoreactive band obtained band was ,42 kDa, similar
to what we have previously reported [24]. This band was chosen
for analysis as it also immunoreacted with anti-Ab monoclonal
antibody 6E10 (Figure 8, top right) and was not present in wild-
type mice (data not shown). pABri vaccination led to a significant
decrease in the levels of A11 immuno reactive (42 kDa) oligomers
(two-tailed t-test, p,0.05; Figure 8, bottom).
G) Assessment of Astrocystosis and Microglial Activation
GFAP immunoreactivity in the cortex and hippocampous in
control Tg mice versus the treated Tg mice did not differ
significantly, although there was a non-statistically significant trend
for a reduction of GFAP immunoreactivity in the cortex of treated
Tg mice (Figure 9A and B). As expected wild-type control mice
had less GFAP immunoreactivity than either Tg mouse group
(Newman-Keuls posthoc test, wild-type controls versus either Tg
controls or Tg treated mice p,0.01 and p,0.05 in the cortex and
hippocampus, respectively).
CD11b immunostaining was performed. CD11b is a well-
established microglial and mononuclear phagocyte marker [31]. The
assessment of microglial marker CD11b was based on semiquantitative
Figure 3. Locomotor activity testing. Shows results of locomotor activity testing comparing Tg control and Tg pABri vaccinated mice. No
significant differences were noted in distance traveled, maximum velocity (Vmax), mean velocity (Vmean) or in resting time.
doi:10.1371/journal.pone.0013391.g003
Figure 4. Cognitive testing on a radial arm maze. The number of
errors is plotted versus the day of testing. There are statistically
significant differences between the untreated control Tg mice versus
the pABri treated Tg mice and wild-type controls. By two-way ANOVA
the treatment effect was p,0.0001. Post-hoc Neuman-Keuls testing
indicated that both the wild-type controls and pABri vaccinated Tg
mice were significantly different from the control Tg mice (p,0.001).
There are no differences between the wild-type controls and the pABri
treated Tg mice.
doi:10.1371/journal.pone.0013391.g004
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resulted in an overall hippocampal and cortical reduction in CD11b
immunoreactivity (Newman-Keuls posthoc test p,0.05 pABri Tg
versus Tg controls in both hippocampus and cortex).
pABri treated mice did not differ significantly by posthoc testing
from wild-type controls, although there was a clear trend for wild-
type mice to have less CD11b immunoreactivity. As expected, wild-
type mice differed significantly from Tg controls (Neuman-Keuls
posthoc test p,0.05 in the hippocampus and p,0.01 in the cortex).
Discussion
In the present study we demonstrate for the first time that
immunization in an AD Tg mouse model with a foreign peptide in
a polymerized, b-sheet rich form is able through conformational
m i m i c r yt oi n d u c ea ni m m u n er e s p o n s et ob o t hA b42 and PHF.
The immunogen we used correspondsto the 13 amino acids of the
carboxyl end of the amyloid that is deposited in British
amyloidosis, where a missense mutation in a stop codon results
in the transcription of a novel intronic sequence [16;17;42]. This
peptide has no homology to known mammalian proteins, but is
highly amyloidogenic [17;43]. As expected, the pABri we used
also induced an immune response to its primary sequence.
Although antibodies to primary amino acid sequences tend to
produce strong reactions with their ligands, this immune response
is very unlikely to be associated with autoimmune toxicity since
normal mice (and other mammals) do not express this peptide as
Figure 5. Quantitation of amyloid burden in the cortex and hippocampus. A) Shows a bar graph of the amyloid quantitation by stereology
in the cortex and hippocampus of Tg control and pABri vaccinated Tg mice. There were significant reductions in the amyloid burden (% area
occupied by 4G8/6E10 immunoreactivity) in both the cortex (85% reduction) and hippocampus (65% reduction); p=0.0001 and p=0.0002,
respectively. C-F show representative immunostained sections with anti-Ab antibodies 4G8 and 6E10 in the cortex (C and D) and in the hippocampus
(E and F) of control Tg mice (C and E) and pABri vaccinated mice (D and F).
doi:10.1371/journal.pone.0013391.g005
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only be found in the very rare individuals who are affected with
British amyloidosis. This immune response is associated with a
strong behavioral rescue in the treated Tg mice as they performed
similar to wild type mice in the radial arm maze. A marked
difference was noted on the radial arm maze from day 1 of the
testing. This is likely related to 4 days of adaptation to the maze
that all the mice had, during which period the wild-type and
treated Tg mice were presumably able to learn the maze partially.
Both the wild-type controls and the treated Tg mice showed
significant learning comparing the error rate from day 1 to day
10, while the Tg non-treated controls showed no significant
learning. The testing of this memory task was not confounded by
any differences in the sensorimotor activity between the control
and vaccinated mice as shown by the locomotor activity, rotarod
and traverse beam testing. Moreover, the behavioral rescue was
associated with a marked reduction in the amyloid burden as
determined histologically and biochemically. The anti-Ab42 titers
our vaccinated mice developed were relatively modest; however,
as we and others have suggested, behavioral rescue is most closely
linked to Ab oligomer reductions and not with either the degree of
amyloid plaque deposition reduction or overall anti-Ab titer
[27;44;45]. Hence, it is not the absolute degree of the humoral
response generated but its quality in terms of effective targeting of
toxic species that is most important. The most toxic forms of Ab
are thought to be oligomeric [41] and importantly we showed that
our approach was associated with a reduction of these toxic
species of Ab. When we used the plasma from pABri immunized
mice to immunolabel control and AD brain tissue, we show that
neuronal perikarya and dystrophic neurites were stained. This is
similar to the pattern previously reported with another anti-
oligomer mouse polyclonal plasma [40]. Presumably this
represents the immunodetection of both intracellular oligomeric
Ab which has been documented in neurons both biochemically
and by microscopic examination [46;47], as well as aggregated,
abnormal tau. The specificity of this reaction was verified by
absorption using aggregated Ab1-42, as well as the lack of
immunolabeling on normal brain tissue. We were also able to
elute the absorbed immune plasma from the aggregated Ab1-42
pellet and show specific labeling of dystrophic neurites. It is likely
that our immunization procedure with pABri lead to an immune
response to a variety of abnormal oligomer and amyloid fibril
Figure 6. Levels of Ab40 and Ab42 in the formic acid and DEA extracted material from brains of control Tg and pABri vaccinated Tg
mice. A) In the formic acid extract fraction Ab40 and Ab43 were reduced 64% and 53%, respectively (*p,0.0001) in the vaccinated mice. B) In the
DEA extracted fraction Ab40 (*p,0.0001) and Ab42 (**p=.0002) were reduced by 71% and 57%, respectively in the vaccinated mice.
doi:10.1371/journal.pone.0013391.g006
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vaccinated Tg mice on normal, aged brain sections. No specific immunolabeling is seen. In AD temporal cortex sections extensive cytoplasmic
neuronal immunoreactivity is evident, shown in B. Absorption of the immune plasma with aggregated Ab1-42 resulted in loss of neuronal
immunolabeling, shown in C. D shows a higher magnification of the lack of specific labeling with plasma from a pABri vaccinated Tg mouse in normal
brain tissue. In E a higher magnification of the neuronal cytoplasmic and dendritic immunolabeling is shown (see arrows). F depicts doubling labeling
where the neuronal staining with the immune plasma is seen in black and neurofibrillary tangle immunolabeling with PHF-1 is seen in red (see
arrows). Hence some neurofibrillary tangles immunolabeled with both PHF-1 and the plasma from pABri vaccinated mice. In G immunostaining with
plasma which had been absorbed with aggregated Ab1-42 on an AD temporal cortex section is shown. H shows immunolabeling in a sequential
section to G using plasma which had been eluted from the aggregated Ab1-42 pellet. I shows immunolabeling with PHF-1 in a sequential section.
The arrows show labeling of dystrophic neurites with the eluted immune mouse plasma in H and with PHF-1. J, K and L depict a similar series of
pictures using a different plasma sample from a Tg mouse immunized with pABri, showing a lack of specific labeling in J, immunolabeling of
dystrophic neurites with the eluted plasma sample in K and the matching PHF1 labeling in L. Rare amyloid b plaques also showed faint
immunolabeling with plasma from pABri immunized mice, as shown in M (see arrows). N shows a double immunolabeling where the plasma from a
pABri immunized mouse is labeling neuronal perikarya and dendrites (see black arrows) and Ab immunoreactivity is seen in red (see red arrows).
There is no co-localization of the plasma immunolabeling with the anti-Ab 4G8/6E10 immunolabeling. O depicts a lack of specific immunolabeling at
a lower magnificent of a similar temporal cortex AD section to M and N where the pre-immune (T0) plasma was used from the same mouse.
doi:10.1371/journal.pone.0013391.g007
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to the behavioral rescue along with the marked reduction in
amyloid burden.
The majority of past active and passive immunization studies
in mouse models and all the past trials in humans have used an
approach where both the normal conformer (sAb)a n dt h e
pathological conformer (Ab) are targeted. This is an important
short coming as interfering with normal sAb will inhibit its
physiological functions such as neuroprotection, modulation of
long term potentiation and innate immunity [48–50]. In the
initial human trial of active vaccination the use of a self-antigen
as an immunogen (Ab42) was associated with encephalitis in
some 6% of patients [11]. This remains an issue with on-going
human trials of passive immunization where a proportion of
participants have developed what has been called vasogenic
edema [51]. We document in the present study that the
treatment with pABri in the Tg mice led to a significant overall
reduction of microglial activation as judged by CD11b
immunoreactivity, with a trend for a reduction in GFAP
immunoreactivity. This is consistent with our use of pABri as
an immunogen which is not associated with excessive CNS
inflammation. We hypothesize that an active immunomodula-
tory approach that, as in our studies, uses an immunogen that
does not correspond to a self-antigen, but through conforma-
tional mimicry is able to induce a response that recognizes
pathological conformers, will be much less likely to be associated
with autoimmune toxicity.
Another significant drawback of the current immunization
approaches tested in humans is that targeting only Ab related
pathology significantly reduces Ab plaques without evidence of a
corresponding significant behavioral rescue in results presented
so far [51;52]. The limited autopsy data from the initial human
active vaccination trial targeting Ab42 showed that patients had
partial or near complete plaque removal and a reduction of Ab
load compared to age matched non-immunized controls.
However, there were no differences between placebo and active
immunization groups in the long-term survival outcome, time to
severe dementia and in cognitive outcome measurements such as
ADAS-Cog, MMSE or DAD [52]. In living patients part of a
passive immunization trial targeting Ab,a2 5 %a m y l o i d
reduction versus controls was documented using PET imaging
studies, in the absence of measurable cognitive benefits [51]. This
suggests that to attain an effective immunotherapeutic approach
the targets should include all forms of Ab toxic conformers and
the tau related pathology. Our conformational mimicry immu-
nomodulatory approach demonstrated that an immune response
was evident both against Ab and PHF pathological forms, as
shown by ELISA measurements and tissue staining of human AD
sections. Normal human brain sections did not show any
immunolabeling with the plasma from pABri vaccinated mice
indicating a specificity for pathology associated protein con-
formers.
In summary we documented a novel active immunization
approach using pABri in a b-sheet rich conformation that targets
Figure 8. Densitometric quantitation of soluble oligomeric Ab.
The levels of pathogenic Ab oligomers in the brain homogenates were
assessed by Western-blot using the A11 oligomer-specific antibody as
illustrated on top left of the figure for two representative brain extracts
from two pABri vaccinated and two control Tg mice.The A11 ,42 kDa
immunoreactive band was also immunoreactive with anti-Ab 6E10
monoclonal antibody (top right of figure). No oligomers were detected
in wild-type mice (data not shown). A bar graph of the densitometric
analysis of the A11 immunoreactive band is shown at the bottom of the
figure (two-tailed t-test, *p,0.05).
doi:10.1371/journal.pone.0013391.g008
Figure 9. Quantitation of Astrocytosis. Reactive astrocytosis was analyzed semiquantitatively on a scale of 0–4 [30]. There was a non-statistically
significant trend for a reduction in GFAP immunoreactivity in the cortex of pABri treated Tg mice versus Tg controls. Wild-type controls had
significant less GFAP immunoreactivity then either Tg mouse group (wild-type controls versus either Tg pABri or Tg controls, p,0.01 and p,0.05 in
the cortex and hippocampus, respectively).
doi:10.1371/journal.pone.0013391.g009
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oligomeric Ab and PHFs. We hypothesize that this type of
immunomodulatory approach may produce interference or
disruption of b-sheet structures in multiple neurodegenerative
diseases associated with pathologic protein conformers.
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